Arkansas is currently home to 671 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Little Rock, Jonesboro, Hot Springs and Fayetteville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Recruiting
This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplat... Read More
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
06/05/2025
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
Recruiting
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: CARTI Cancer Center, Little Rock, Arkansas
Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Recruiting
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Highlands Oncology Group, Springdale, Arkansas
Conditions: Carcinoma, Non-Small-Cell Lung
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Recruiting
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Investigative Site US045, Fort Smith, Arkansas
Conditions: Hidradenitis Suppurativa (HS)
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Recruiting
The primary objective of the trial is to evaluate the efficacy of fluticasone propionate/albuterol sulfate multidose dry powder inhaler with electronic module (Fp/ABS eMDPI). Secondary objectives are: * To evaluate the efficacy of Fp/ABS eMDPI administered four times daily * To evaluate the safety and tolerability of Fp/ABS eMDPI administered four times daily over four weeks * To investigate the pharmacokinetics of Fp/ABS eMDPI, ABS eMDPI and Fp eMDPI after administration of a single dose The... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/04/2025
Locations: Teva Investigational Site 12102, Little Rock, Arkansas
Conditions: Asthma
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Recruiting
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Highlands Oncology, Fayetteville, Arkansas
Conditions: Metastatic Castration-Resistant Prostate Cancer
A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
Recruiting
The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo. A secondary objective is to further evaluate the safety of TEV-53408. The planned study period per participant is 84 weeks including a screening period (up to 4 weeks), a 24-week open-label treatment period, a 16-week washout period, and a 40-week follow-up period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2025
Locations: Teva Investigational Site 12052, Hot Springs, Arkansas
Conditions: Vitiligo
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Recruiting
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
06/04/2025
Locations: Premier Dermatology Clinical Trials Institute At Northwest Arkansas, Fayetteville, Arkansas
Conditions: NonSegmental Vitiligo
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Recruiting
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2025
Locations: Premier Dermatology Clinical Trials Institute At Northwest Arkansas, Fayetteville, Arkansas
Conditions: Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
Recruiting
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2025
Locations: Premier Dermatology Clinical Trials Institute At Northwest Arkansas, Fayetteville, Arkansas
Conditions: Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Recruiting
The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2025
Locations: 89bio Clinical Study Site, Little Rock, Arkansas
Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Recruiting
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Mercy Hospital Fort Smith, Fort Smith, Arkansas
Conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Non-Small Cell Carcinoma, Melanoma, Non-Hodgkin Lymphoma